obesity
Investing.com — The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly three-quarters of the U.S. population categorized as overweight or obese and similar trends emerging in countries like Mexico, Australia, and the United Kingdom (TADAWUL:), the burden of obesity-related health complications…
Investing.com — Weight-loss medications like the popular versions made by Denmark’s Novo Nordisk A/S (CSE:) and US peer Eli Lilly (NYSE:) are the “most compelling story within the healthcare sector,” analysts at Wells Fargo said. The GLP-1 class of drugs includes blockbuster brands like Novo’s Ozempic and Wegovy and Eli Lilly’s…
Novo Nordisk (NYSE:) reported a robust first quarter with a 24% increase in sales at constant exchange rates (CER), reaching DKK 65.35 billion. The company’s operating profit also saw a significant rise, jumping by 30% at CER to DKK 31.8 billion. Despite these strong results, shares of the pharmaceutical giant…
By Maggie FickLONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly (NYSE:).The company has quadrupled its U.S. supply of starter doses…
